Solid Biosciences (SLDB) Net Income towards Common Stockholders (2017 - 2024)
Historic Net Income towards Common Stockholders for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$38.0 million.
- Solid Biosciences' Net Income towards Common Stockholders fell 8463.55% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 2418.8%. This contributed to the annual value of -$120.6 million for FY2024, which is 2418.8% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' Net Income towards Common Stockholders is -$38.0 million, which was down 8463.55% from -$32.9 million recorded in Q3 2024.
- Solid Biosciences' Net Income towards Common Stockholders' 5-year high stood at -$19.0 million during Q2 2020, with a 5-year trough of -$38.0 million in Q4 2024.
- Its 4-year average for Net Income towards Common Stockholders is -$25.6 million, with a median of -$24.9 million in 2023.
- Per our database at Business Quant, Solid Biosciences' Net Income towards Common Stockholders soared by 3761.81% in 2023 and then tumbled by 8463.55% in 2024.
- Solid Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$21.4 million in 2020, then plummeted by 54.62% to -$33.0 million in 2022, then soared by 37.62% to -$20.6 million in 2023, then crashed by 84.64% to -$38.0 million in 2024.
- Its Net Income towards Common Stockholders was -$38.0 million in Q4 2024, compared to -$32.9 million in Q3 2024 and -$25.3 million in Q2 2024.